Novos Trial Of Weight-loss Drug Shows Improvement In Fatty Liver Disease
Novo nordisk a/s specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: Nov 1, 2024 7:25am. Novo nordisk will seek regulatory approval of semaglutide, the key ingredient in its popular weight loss medicine, in a common liver disease following positive results in a. Accumulating evidence has shown that weight loss, whether achieved by diet and lifestyle interventions, bariatric surgery or pharmacotherapy, can improve biomarkers of nafld, as.
liver disease alcoholic fatty non treatments future cancers fight against current